|
|
||||||||
1 Program in Cardiovascular Gene Therapy, Cardiovascular Research Center, Massachusetts General Hospital
2 Harvard Medical School, Boston
3 Gwathmey Inc., Cambridge, Massachusetts
4 Morehouse School of Medicine, Department of Surgery, Atlanta, Georgia
| ABSTRACT |
|---|
|
|
|---|
cardiac; gene therapy; rats
| INTRODUCTION |
|---|
|
|
|---|
Gene therapy is rapidly becoming an experimental treatment modality in heart failure (8), especially for patients where cardiac transplant is not an option. Animal models of heart failure are needed to enable investigators to evaluate the therapeutic effect and physiological function of genes delivered by gene transfer in vivo prior to studies in humans. Multiple animal models of left heart failure have been established in experimental research (1, 2, 7, 16). Aortic banding, coronary ligation, or administration of cardiotoxic substances such as adriamycin have frequently been used in rodents, whereas rapid pacing and emboli-induced infarction are more often used in large animal models (1, 2, 7, 16).
With aortic banding an increase in cardiac afterload is induced by placing a metal clip on the ascending aorta (14). Depending on the diameter of the clip, heart failure can develop in rats within 2030 wk. The timing and progression to hypertrophy and heart failure is impacted by species, age at the time of banding, and the degree of stenosis applied (14). Nevertheless, this model, which closely mimics chronic hemodynamic stress or load seen in clinical heart failure, has proven useful in studying the progression to hypertrophy and transition to heart failure.
Commonly used surgical approaches in rats often results in extensive thoracic scaring, fibrous adhesions, and epicardial inflammatory cell infiltration. To investigate the efficiency of gene transfer in the setting of hypertrophy and heart failure as well as improve the utility of the aortic banded rat model in gene transfer experimentation, we have developed a new surgical approach to aortic banding to dissociate transgene-associated inflammatory cell infiltration and approach-induced scarring and adhesions which might impact global cardiac function and survival. This study was undertaken to determine whether a replication-deficient adenovirus can induce efficient gene transfer into adult cardiac myocytes undergoing hypertrophy and transition to heart failure in vivo. Here we demonstrate a novel surgical technique for aortic banding which enables homogenous adenoviral-mediated gene transfer in both hypertrophied and failing hearts.
| METHODS |
|---|
|
|
|---|
|
Construction of E1-deleted recombinant adenoviral vectors.
A first generation type 5 recombinant adenovirus was used in these studies encoding for the green fluorescent protein (GFP) under the control of the cytomegalovirus promoter (CMV). Ad.GFP was constructed through homologous recombination in Escherichia coli bacteria by using pAdTRACK/Easy system (13). The recombinant virus was prepared as high-titer stocks by propagation in 293 cells as previously described (911, 13). The titer of stock used for these studies measured by plaque assays was as follows: 2 x 1010 pfu/ml for Ad.GFP. A second adenovirus, Ad.ßgal, was constructed in a similar fashion with ß-galactosidase (ß-gal) also under the control of CMV. A third virus with no insert or promoter was also constructed (Ad.Ø).
Adenoviral delivery protocol.
The chest was entered by a median sternotomy. A 22-gauge catheter containing 100 µl of adenoviral solution was advanced from the apex of the LV to the aortic root. The aorta and pulmonary arteries were clamped distal to the site of the catheter, and the solution was injected. The clamp was maintained for 30 s. This procedure allows the solution that contains the adenovirus to perfuse the coronary arteries of the heart. After removal of air and blood, the chest was closed. We have noted that the "blanching" of the heart during the injection and cross-clamping is a hallmark for effective gene transfer. We therefore ensured that during the surgical procedure and adenoviral gene delivery this blanching was observed.
Experimental groups.
In the first group of animals we used 60 rats aged 4 wk as described above. Thirty animals were randomized in the banding group, and thirty animals were randomized in the sham group. Immediately postoperatively and within 2 wk of surgery, six animals died in each group. Therefore, 24 animals in each group were followed by echocardiography. At the end of the study, 27-wk postbanding, 15 animals in each group were studied morphologically, and the rest of the tissues were used for protein analyses.
In a second group of animals, 10 rats aged 12 wk underwent either injection with either Ad.ßgal and the empty adenovirus (Ad.Ø). The animals were studied 24 days following injection.
Histochemistry and fluorescence detection.
A subset of the hearts which were infected with Ad.ßgal were examined by immunohistochemistry to evaluate the expression of ß-gal. Hearts were fixed with a PBS containing 0.5% glutaraldehyde for 30 min and then in PBS with 30% sucrose for 30 min. The hearts were then permeabilized by incubation in solution containing sodium deoxycholate (0.01%) and Nonidet P-40 for 15 min. The hearts were then incubated overnight in a solution containing 5-bromo-4-chloro-3-indolyl-ß-D-galactopyranoside (X-Gal), and 10-µm sections were then cut and examined under light microscopy. Lungs, livers, and full-length aorta were also fixed and examined in a similar fashion.
The subset of animals which were infected with Ad.GFP were examined by fluorescent microscopy. The hearts were quickly removed and perfused in a retrograde fashion using PBS to remove blood products. The hearts were then cut in the midventricular area using 10-µm sections. These sections were first visualized with white light and then by fluorescence microscopy at 510 nm with single excitation peak at 490 nm of blue light.
Gross morphology.
Hearts were harvested after four days posttransgene delivery and sectioned. The following morphological measurements were taken: heart weight, body weight, and tibial length. Heart weight/tibial length and heart weight/body weight ratios were calculated as indicators of myocardial enlargement.
Statistics.
Data are presented as mean ± SD. A two-tailed unpaired Students t-test was performed to determine significance. A statistical significance was accepted at a the level of P < 0.05.
| RESULTS |
|---|
|
|
|---|
|
|
|
|
|
|
|
|
| DISCUSSION |
|---|
|
|
|---|
Although molecular techniques have made giant steps forward, the methods for inducing reproducible and highly consistent surgical models in small rodents has lagged behind the improvements in molecular biology techniques. However, with the development of rodent models, there arise several clearly recognized needs: 1) a need to fully explore the phenotype at the whole organ and in vivo animal level and 2) the need to evaluate them at the molecular or genetic level (2, 4, 5). Microsurgical interventions used to study the interrelationship of genes and pathophysiology in vivo is a powerful approach. Surgical models may resemble the pathophysiological response to chronic hemodynamic stress or load, thereby resembling components of clinical heart failure seen in humans. Although techniques for exploring aspects of cardiac function are well developed for larger species, their modification for the small size of rodents with rapid heart rates and small surgical planes has proven a formidable challenge.
Using this approach, we obtained a model of hypertrophy and heart failure that allows a less challenging second surgical intervention for the in vivo transduction of adenoviral genes.
In vivo transduction by adenoviral gene transfer.
We have previously reported that the catheter-based adenoviral technique induces global gene transfer in adult rat hearts with an expression pattern that is grossly global throughout the ventricle (3, 11). In single myocytes isolated from the infected hearts, we have also previously reported that
5070% of cardiomyocytes were expressing the reporter transgene (3, 11). Even though not every single cardiomyocyte was infected, we have shown previously that this degree of myocyte transduction was sufficient to induce morphological and physiological changes. Together our data using reporter constructs demonstrates highly effective gene transfer to adult rat hearts with hypertrophy and heart failure in vivo.
It has been reported that coronary reserve is decreased in the setting of heart failure (15). This might be expected to impact our delivery method and efficiency of gene transfer. However, we obtained similar levels of efficiency for both control aged matched rats as seen with hypertrophied hearts and failing hearts. These data indicate that in the presence of differences in coronary reserve and/or flow, our method of gene delivery can still result in significant transgene expression levels.
Recombinant adenoviral vectors offer the opportunity to investigate the role of local signal transduction pathways in the pathogenesis of heart failure both in vitro and in vivo. Recombinant adenoviral vectors offer several significant advantages: the viruses can 1) be prepared at extremely high titer, 2) successfully infect non-replicating cells, and 3) confer high-efficiency and high-level transduction of cardiocytes. Transgenic approaches targeting specific proteins in the signaling pathway are also possible. Furthermore, adenoviral transduction offers several advantages over transgenic approaches. First, developmental issues can be removed from consideration by working in adult animals and in vivo systems. For example, transgenic mice have been generated by overexpressing SERCA2a or by knocking out phospholamban. However, these animals develop changes in other calcium cycling proteins that dilute the direct effects of overexpression of the cDNA of interest (12). The differences in the phenotype seen in transgenic mice may be related to differences in the timing and/or level of transgene expression or differences in genetic backgrounds. Second, the high efficiency of adenoviral transduction makes feasible expression of multiple exogenous cDNAs. In this way, one can potentially deduce whether effects involve overlapping or distinct mechanistic pathways. We previously demonstrated that coinfection of neonatal rat myocytes with two viruses did not significantly alter the expression level of either transgene, compared with myocytes infected with one virus alone (10). Third, adenoviral vectors can be used in vitro and in vivo, as well as in multiple species, thus providing optimal flexibility in selecting a model (911). Fourth, with the use of adenoviral vectors that simultaneously encode for GFP, investigators can rapidly identify the distribution of the transgene delivery and expression as well as identify individual cells that are expressing the transgene of interest and study these single cells functionally. The major disadvantages to adenoviral gene transfer have been its transient expression and the host immune/inflammatory response to the vectors themselves (6). Gene transfer to adult myocardium in vivo has generally been found to mediate a high level of expression for
1 wk. By 24 wk after infection, transgene expression has usually either declined dramatically or been extinguished completely. Furthermore, it has been suggested that late inflammation can conceivably be exacerbated by the mechanical trauma of gene delivery approaches (6). By reducing myocardial trauma using our approach to gene delivery, one should be able to avoid exacerbation of inflammatory responses.
Adenoviral gene transfer to rodent hearts has been largely performed by direct injection into the myocardium. This has usually resulted in focal areas of overexpression of the gene carried by the adenovirus and inflammatory responses. Some of the disadvantages of this method are 1) direct injection results in damage to muscle tissue at the site of injection, and 2) the overexpression is focal rather than homogeneous and therefore is unlikely to modulate global cardiac function. Therefore, a catheter-based technique was previously developed to deliver adenoviruses to the heart in a global fashion (11). This technique offers the distinct advantage over established methods of gene delivery to the heart in that the overexpression is global in distribution and the coronary arteries do not have to be manipulated, a procedure that carries a very high mortality in rodents. Using this combined approach, we have achieved global cardiac transgene expression in a model of hypertrophied and heart failure.
Our novel approach will enable investigators to deliver transgenes without extensive cardiac adhesions and increased scarring due to surgical manipulation, thereby enabling an easier second surgical manipulation and a clearer picture of the effects of transgene delivery on cardiac function as opposed to a complicated picture that results from the surgical intervention.
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
Address for reprint requests and other correspondence: R. J. Hajjar, Cardiovascular Research Center, Massachusetts General Hospital East, 149 13th St., CNY-4, Rm. 4215, Charlestown, MA 02129-2060 (E-mail: hajjar{at}cvrc.mgh.harvard.edu).
10.1152/physiolgenomics.00035.2001.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
J. M. O'Donnell, A. Fields, X. Xu, S. A. K. Chowdhury, D. L. Geenen, and J. Bi Limited functional and metabolic improvements in hypertrophic and healthy rat heart overexpressing the skeletal muscle isoform of SERCA1 by adenoviral gene transfer in vivo Am J Physiol Heart Circ Physiol, December 1, 2008; 295(6): H2483 - H2494. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Cingolani, G. A. Ramirez Correa, E. Kizana, M. Murata, H. C. Cho, and E. Marban Gene Therapy to Inhibit the Calcium Channel {beta} Subunit: Physiological Consequences and Pathophysiological Effects in Models of Cardiac Hypertrophy Circ. Res., July 20, 2007; 101(2): 166 - 175. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Yin, L. Chao, and J. Chao Kallikrein/Kinin Protects against Myocardial Apoptosis after Ischemia/Reperfusion via Akt-Glycogen Synthase Kinase-3 and Akt-Bad{middle dot}14-3-3 Signaling Pathways J. Biol. Chem., March 4, 2005; 280(9): 8022 - 8030. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Lebeche, R. Kaprielian, F. del Monte, G. Tomaselli, J. K. Gwathmey, A. Schwartz, and R. J. Hajjar In Vivo Cardiac Gene Transfer of Kv4.3 Abrogates the Hypertrophic Response in Rats After Aortic Stenosis Circulation, November 30, 2004; 110(22): 3435 - 3443. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Li, T. Ha, X. Gao, J. Kelley, D. L. Williams, I. W. Browder, R. L. Kao, and C. Li NF-{kappa}B activation is required for the development of cardiac hypertrophy in vivo Am J Physiol Heart Circ Physiol, October 1, 2004; 287(4): H1712 - H1720. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Yin, L. Chao, and J. Chao Adrenomedullin Protects Against Myocardial Apoptosis After Ischemia/Reperfusion Through Activation of Akt-GSK Signaling Hypertension, January 1, 2004; 43(1): 109 - 116. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Houser and K. B. Margulies Is Depressed Myocyte Contractility Centrally Involved in Heart Failure? Circ. Res., March 7, 2003; 92(4): 350 - 358. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. del Monte and R. J Hajjar Targeting calcium cycling proteins in heart failure through gene transfer J. Physiol., January 1, 2003; 546(1): 49 - 61. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |